85 results about "Ischemic injury" patented technology

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

The disclosed physiological feedback systems and methods assist with assessing, monitoring and / or treating a patient experiencing a cardiac arrest event. The systems and methods receive multiple inputs and are continuous and / or iterative during a treatment session to provide physiological state trends of the patient. An index of the physiological state of the patient can be derived and confounders, and / or their effects, can be identified, and / or removed, from the index. Additionally, the systems and methods can assist with determining ischemic injury in a patient based on cerebral tissue oxygenation and / or other physiological data.

The invention discloses a small molecular proteasome agonist as well as a preparation method and application thereof. According to the invention, cyclohexylamine is used as an initial raw material, and 3-(1-(benzo [D] thiazole-2-carbonyl)-2-(furan-2-methylene) hydrazone group)-N-cyclohexylpropanamide and N-cyclohexyl-3-(2-(furan-2-methylene)-1-(quinoline-2-carbonyl) hydrazone group) propanamide are prepared through a five-step reaction. The two compounds provided by the invention have good 20S proteasome agonistic activity and ischemic injury myocardial cell protection activity, do not have obvious cytotoxicity, and are expected to become effective choices for ischemic cardiomyopathy and other proteotoxic diseases.

This invention relates to the field of ischemic injury model construction technology, and particularly to a method for constructing a mouse ischemic injury model for evaluating the protective effect of GDF-15. The method includes acquiring a dataset of mouse physiological parameters to determine physiological feature vectors, thereby determining an individual vulnerability index and performing similarity matching with the vulnerability index of a specific individual. Based on the matching results, a matching sample set is constructed, and then an ischemic injury model is constructed using a deep learning network model. The model is then dynamically simulated using the specific individual vulnerability index, specific intermediate monitoring data, and specific infarct area percentage data to output a simulated protective effect index to determine if the model is qualified. If unqualified, the similarity matching threshold is adjusted based on the degree of deviation, and the matching and model construction are repeated. This invention significantly improves the uniformity and construction success rate of the ischemic injury model through individualized matching and dynamic feedback optimization, providing a reliable model for evaluating the protective effect of GDF-15.

This invention relates to the field of medical and health device technology, and discloses a wearable AI-assisted pressure-controlled ischemia pretreatment training device, including a support base. A support plate is fixedly connected to the inner side of the support base, and a restraint strap is detachably connected to the inner side of the support plate. Two airbags are installed inside the restraint strap. Two fixed cylinders are fixedly connected to the outer side of the support base. A connecting tube 1 and a connecting tube 2 are sequentially connected to the outer side of each fixed cylinder. The end of the connecting tube 2 away from the fixed cylinder is connected to the interior of the airbags. A movable plate is slidably connected inside the fixed cylinders, and a movable rod is fixedly connected to the outer side of the movable plate. By setting up airbags 1 and 2 and combining them with an AI pretreatment training system, coordinated ischemia and reperfusion training of two target organs (finger and arm) can be achieved. This dual-site training stimulates a stronger anti-ischemic injury protection mechanism in the body, broadening the applicable population and training scenarios of the device.

A multimodal optical imaging platform is used to obtain cerebral perfusion-metabolism mismatch metrics for rapid assessment of acute brain injury, ongoing (real-time) feedback to optimize cardiopulmonary resuscitation to improve neurological outcome, and rapid prognosis of recovery. Light of several wavelengths and types is delivered to the tissue, which is then absorbed and scattered by tissue components such as blood and cellular components. Some of this light scatters back to the surface, where it is captured by a detector. The resulting data are processed to obtain blood flow and oxygenation parameters, as well as tissue scattering. These parameters are then combined to calculate metabolism and flow-metabolism coupling / decoupling metrics, which are used to determine ischemic damage, ongoing need for optimal blood flow and oxygenation, and to predict cerebral recovery in patients with acute brain injury during and immediately after cardiac arrest, stroke, traumatic brain injury, etc.

The invention discloses a traditional Chinese medicine composition for treating acute myocardial infarction, a pharmaceutical preparation and application thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-18 parts of ginseng, 3-6 parts of pseudo-ginseng, 9-18 parts of ligusticum wallichii, 12-24 parts of radix achyranthis bidentatae, 6-12 parts of fructus forsythiae and 9-18 parts of radix curcumae. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention has the beneficial effects that (1) the traditional Chinese medicine composition provided by the invention can reduce the myocardial infarction area after ischemia, inhibit myocardial fibrosis and improve heart structure and function changes caused by acute ischemic injury; and (2) the traditional Chinese medicine composition provided by the invention can effectively inhibit oxidative stress reaction and relieve mitochondrial injury, thereby playing a role in protecting the heart. And (3) the traditional Chinese medicine composition has the advantage of good safety and can be taken for a long time.

The application relates to a dual-purpose maintenance system for taking out a heart and maintaining the heart extracorporeally, which comprises a perfusion pipeline assembly and an organ box. The design that the organ box is communicated with a blood storage container and is switched can support the no-stop-taking-out and transportation operation of the heart. In the conversion process, the pipeline does not need to be replaced, the heat ischemic injury and ischemia-reperfusion injury of the heart are reduced.

The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.

To provide a method of treating cardiac fibrosis in a patient.SOLUTION: The present invention relates to a method of treating cardiac fibrosis in a patient, comprising administering to the patient a therapeutically effective amount of an αV-integrin inhibitor. Pharmacological blockade of αV-containing integrins improved cardiac function and survival after MI by reducing infarct size and attenuating expansion of reactive cardiac fibrosis. Notably, after pharmacological blockade of αV-containing integrins, a total myocardial fibrogenesis area as well as interstitial fibrosis in the remote myocardial area are significantly reduced. These data identify a novel mechanism regulating cardiac fibrosis in response to an ischemic injury and suggest that pharmacological targeting of αV-integrins may provide clinical benefit in the treatment of cardiac fibrosis.SELECTED DRAWING: None

The invention provides a nasogastric tube fixing device which comprises a fixing part, a bandage, a nose-shaped support and a first clamping groove, the fixing part is of an arc-shaped structure, the nose-shaped support and the fixing part are connected through an inverted-L-shaped connecting rod, mounting parts are symmetrically arranged on one side of the fixing part, an adjusting belt of an arc-shaped structure is connected between the two mounting parts, and the first clamping groove is formed in the adjusting belt. The adjusting belt is sleeved with a first loop, a first clamping groove in the same direction as the nostrils is fixedly formed in the side, away from the fixing piece, of the first loop, the first clamping groove is used for clamping and fixing the stomach tube, the two ends of the bandage are connected with the two ends of the fixing piece respectively, and a nanoscale flexible pressure sensor is embedded in the nose-shaped support. The pressure sensor is connected with the controller through a signal line, and the controller is connected with the monitoring terminal through a wireless signal; the device solves the problem of skin injury caused by repeated adhesion of an adhesive tape, ensures blood supply safety of nasal mucosa, reduces the risk of ischemic injury, and avoids medical negligence caused by aspiration of a stomach tube.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response activation and / or the antioxidant response and include for example. HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response and / or the antioxidant response and include for example, HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

Methods and pharmaceutical compositions for treating stroke, intracranial hemorrhage and ischemic injury. The methods include administering a therapeutically effective amount of a matrix metalloproteinase 9 (MMP-9) antibody or antigen-binding fragment thereof that specifically binds MMP-9 and reduces MMP-9 activity, which treats stroke caused by intracranial hemorrhage and / or ischemic injury in a subject.

The invention relates to the field of medical instruments, and discloses an external perfusion assembly and a perfusion balloon catheter. The external perfusion assembly is suitable for being arranged on the outer side of the balloon in a sleeving mode and comprises a communication unit and two elastic hoops. The communication unit comprises a deformation section and a connection section. The device is provided with the perfusion cavity independent of the balloon, blood can continuously flow to the downstream through the channel, ischemic injury caused by blood flow blockage of a traditional balloon is avoided, and the safe operation time is prolonged; when the balloon contracts, the deformation section resets in the radial direction, the elastic hoop and the connecting section provide restraining force for the deformation section, so that the deformation section automatically resets along with contraction of the balloon, the situation that blood vessels are damaged when an instrument is withdrawn can be avoided, and meanwhile positioning flexibility is enhanced. Compared with a complex integrated forming process of a traditional multi-cavity balloon, the independent external perfusion assembly is connected with the standard balloon in a sleeving mode, the balloon does not occupy the circulation space of blood when expanded, the manufacturing process is separated, the structure is simplified, the process is optimized, and the production cost is reduced.

The application belongs to the technical field of biological medicine, and particularly relates to umbilical cord mesenchymal stem cells and a preparation method and application thereof. The preparation method takes umbilical cord Wharton's jelly as raw material, and obtains high-purity umbilical cord mesenchymal stem cells through cleaning treatment, tissue block preparation, serum-free culture and liquid change subculture. The culture conditions and operation parameters are strictly controlled in the preparation process, the MSC serum-free culture medium and trypsin substitutes are used, so that the cell activity and purity can be guaranteed. The umbilical cord mesenchymal stem cells have no obvious toxicity and tumorigenic risk under a safe dose, and have no damage to organs in long-term use. The umbilical cord mesenchymal stem cells can significantly improve the motor dysfunction after cerebral ischemia, reduce the volume of cerebral ischemic injury, protect the integrity of the blood-brain barrier, reduce the neuroinflammatory response, and play a multi-dimensional role in brain tissue protection and repair, thereby providing a new effective means for the treatment of ischemic stroke, and having important clinical transformation value and application prospect.

The invention discloses a screening method of anti-cerebral ischemic injury active components of a salvia miltiorrhiza-cortex moutan medicine, a targeted brain-entering composition and application thereof, and belongs to the technical field of traditional Chinese medicines. The pharmaceutical composition for resisting cerebral ischemic injury is prepared by compatibility of radix salviae miltiorrhizae and cortex moutan, blood-entering active components of the pharmaceutical composition comprise various components such as gallic acid, and paeoniflorin and the like are targeted brain-entering components. The invention also provides a method for screening the active ingredients of the composition in blood, which comprises the following steps: preparing a test sample and a mixed reference substance solution, and analyzing and determining the ingredients by high performance liquid chromatography and high resolution mass spectrometry. The composition can be used for preparing drugs for resisting cerebral ischemia injury, can improve the neurological function of rats and the like, and is suitable for treating acute and chronic cerebral ischemia and reperfusion injury. In addition, the active ingredients entering blood can be used for preparing drugs for promoting angiogenesis of cerebral vessels, and the BMECs related capacity of OGD / R damaged rats is improved. The invention provides a new direction and choice for treatment of cerebral ischemia injury.

The application relates to the technical field of biological medicine, and discloses medical uses of HSPD1 acetylation modification in prevention or treatment of myocardial infarction. The application first finds that the acetylation level of an HSPD1 protein K352 site is specifically up-regulated in the pathological process of myocardial infarction, and that the heart function after myocardial infarction can be significantly improved by up-regulating the acetylation level of the site, and myocardial fibrosis and myocardial cell hypertrophy can be inhibited; the acetylation level of the site is down-regulated, and myocardial ischemic injury is aggravated, and the heart function is deteriorated. The application confirms that the HSPD1 K352 site acetylation can be used as a new target point for prevention, treatment and auxiliary diagnosis of myocardial infarction, and provides a theoretical basis and experimental basis for research and development of myocardial infarction targeted drugs and gene therapy products.

The invention relates to a dietary therapy formula for repairing ear hearing nerve cells and a preparation method thereof. Components with homology of medicine and food are optimally selected, the salvia miltiorrhiza and the radix puerariae can increase blood flow of inner ears, promote nutrition delivery, inhibit vasospasm of the inner ears and reduce ischemic injury of hair cells, alpha-linolenic acid is provided for a human body by utilizing the flaxseeds and the walnuts and converted into DHA, the DHA directly participates in nerve myelin sheath reconstruction, auditory nerve signal conduction is enhanced, and the health care effect is achieved. Chinese yam and astragalus membranaceus can provide Chinese yam polysaccharide and astragaloside, the mitochondrial function is improved, and cell apoptosis is delayed. The whole component is low in sugar content, is suitable for diabetics, expands the application crowd and non-medicine products, can reduce the psychological burden of eaters taking medicines for a long time, and is beneficial to popularization and application.

A use of N-lactoyl-phenylalanine (Lac-Phe) in a preparation of a medicament for preventing and / or treating ischemic heart disease is provided. It is the first to demonstrate that Lac-Phe can improve the cardiac function in a mouse model of left anterior descending coronary artery stenosis, promote cardiac angiogenesis, improve the viability of hypoxic cardiomyocytes, and inhibit the expression of inflammatory cytokines in the heart, thereby playing an anti-myocardial ischemic injury role. Therefore, the Lac-Phe can be used to prepare a medicament for treating ischemic heart disease. A novel technical means for the treatment of ischemic heart disease is provided.

Methods and devices for the nasal administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease / impair blood flow and or oxygen delivery to the nervous system.

Materials and methods for restoring an ex vivo organ prior to transplantation of the organ into a subject in need thereof are provided. The methods and materials are useful for treating, improving, restoring, and / or regenerating organs, such as kidney and liver, the organ is aged and / or characterized by organ injury caused by ischemic injury, toxic injury, perfusion injury, hypertension injury, immune injury, physical injury, steatosis, virus-induced hepatitis, alcohol or fibrosis irrelevant to any known cause. Materials and methods provided may increase the available library of donor organs, such as kidneys and livers. In addition, the provided materials and methods can treat organs that are then autotransplanted.

The invention relates to the technical field of image analysis of injury models, in particular to an in-vivo and in-vitro modeling method for myocardial infarction ischemic injury, which comprises the following steps of: determining an injury dilation prediction sequence of each myocardial sub-region by pre-constructing a blood supply association relationship between each myocardial sub-region and each blood supply artery; the method comprises the following steps: determining whether a myocardial infarction and ischemic injury sample model is qualified or not by acquiring the confidence coefficient of each myocardial infarction region contour section, pre-regulating and controlling the injury of the ischemic injury, redefining the myocardial infarction region contour section with the suspected confidence coefficient, and judging whether the myocardial infarction and ischemic injury sample model is qualified or not according to the difference quantity of injury characterization quantities in a continuous injury identification period. According to the method, a GDF-15 research test is carried out on a qualified myocardial infarction ischemic injury sample model, so that the injury expansion of an infarction area is predicted in the continuous batch construction process of the myocardial infarction ischemic injury model, the model construction process is regulated and controlled in a targeted manner, and the uniformity and effectiveness of continuous construction of the model are improved.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia / ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg / hr and about 300 μg / hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

The application discloses a myocardial ischemic injury marker CAPG and application thereof. The application finds that down-regulation of CAPG expression can improve myocardial cell apoptosis and heart function after myocardial infarction by injecting AAV9-shCAPG virus into the tail vein of a mouse model of myocardial infarction. The application first discloses a new use of macrophage capping protein (CAPG) as a therapeutic target and a diagnostic target of myocardial ischemic injury, provides a new drug action target for diagnosis and treatment of myocardial ischemic injury, and has very important clinical transformation value. As a diagnostic marker of myocardial ischemic injury, CAPG can be conveniently detected by using an existing enzyme-linked immunosorbent assay kit, has the advantage of rapid detection, and can be conveniently detected by only extracting a small amount of peripheral venous blood of a patient.

The present invention provides a pharmaceutical composition, which is an aqueous solution containing Compound (I) (also known as U0126) or a pharmaceutically acceptable salt thereof at a concentration of 50-200 μM, further comprising 0.2-1.0% (v / v) polyoxyethylene castor oil. The composition is particularly useful in treating ischemic injury (particularly subarachnoid hemorrhage) in human patients by direct injection into the brain. Uses of the composition, unit doses containing the composition, and methods of using the composition are also disclosed. [Formula 1] TIFF2026501344000012.tif40159

The present invention provides a pharmaceutical composition which is an aqueous solution comprising Compound (I) (also known as U0126) or a pharmaceutically acceptable salt thereof at a concentration of 50 [mu] M to 200 [mu] M, and wherein the solution further comprises 0.2% to 1.0% (v / v) polyoxyethylated castor oil. The compositions are particularly useful for the treatment of ischemic injury, in particular subarachnoid hemorrhage, in human patients by direct injection into the brain. Uses of the compositions, unit doses containing the compositions and methods of using the compositions are also disclosed. # imgabs0 #

A multimodal optical imaging platform is used to obtain cerebral perfusion-metabolism mismatch metrics for rapid assessment of acute brain injury, ongoing (real-time) feedback to optimize cardiopulmonary resuscitation to improve neurological outcome, and rapid prognosis of recovery. Light of several wavelengths and types is delivered to the tissue, which is then absorbed and scattered by tissue components such as blood and cellular components. Some of this light scatters back to the surface, where it is captured by a detector. The resulting data are processed to obtain blood flow and oxygenation parameters, as well as tissue scattering. These parameters are then combined to calculate metabolism and flow-metabolism coupling / decoupling metrics, which are used to determine ischemic damage, ongoing need for optimal blood flow and oxygenation, and to predict cerebral recovery in patients with acute brain injury during and immediately after cardiac arrest, stroke, traumatic brain injury, etc.